While Fiasp is now the only ultra fast insulin on the market, it won’t be the new kid for long. At least two other compa…
Rapid Insulin
Biodel Initiates a Phase 2 Study of Ultra-Rapid-Acting Insulin
Biodel has initiated a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting meal…
NIH Awards Biodel Grant to Develop Ultra-Rapid-Acting Insulin for Use in Artificial Pancreas
The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel a gr…
Biodel Obtains Technologies for Development of Glucagon Formulations
Biodel Inc. has partnered with Aegis Therapeutics, LLC (Aegis) and has obtained exclusive worldwide license to Aegis' pr…
Positive Results for Biodel’s Ultra Rapid Acting Insulin
Biodel Inc. announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BI…
Positive Phase 2 Results for Halozyme’s Ultra Fast Insulins
Halozyme Therapeutics, a San Diego based biopharmaceutical company, announced positive results from two Phase 2 clinical…
Biodel’s Ultra Rapid Insulin Fails in Second Phase 1 Trial
Biodel's ultra-rapid-acting formulations of recombinant human insulin, BIOD-105 and BIOD-107, failed to meet the company…
Biodel’s Ultra-Rapid-Acting Insulin Formulations to be Tested in Patients Using Insulin Pumps
Biodel announced that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations…
Biodel to Accelerate Development of Ultra-Rapid-Acting Insulins
Biodel Inc. has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clin…
FDA Issues Complete Response Letter to Biodel New Diabetes Drug Application
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) requesting additional information re…
